[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Matinas Biopharma Hl (MTNB)

Matinas Biopharma Hl (MTNB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,596
  • Shares Outstanding, K 6,406
  • Annual Sales, $ 0 K
  • Annual Income, $ -10,350 K
  • EBIT $ -7 M
  • EBITDA $ -7 M
  • 60-Month Beta 1.71
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.57
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.99
  • Most Recent Earnings $-0.30 on 05/08/26
  • Next Earnings Date 08/13/26 [--]
  • Annual Dividend & Yield (Fwd) 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Drugs

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.2312 +4.41%
on 07/24/26
0.9065 -73.37%
on 07/10/26
-0.4086 (-62.86%)
since 06/24/26
3-Month
0.2312 +4.41%
on 07/24/26
0.9065 -73.37%
on 07/10/26
-0.3686 (-60.43%)
since 04/24/26
52-Week
0.2312 +4.41%
on 07/24/26
3.0900 -92.19%
on 08/15/25
-0.7086 (-74.59%)
since 07/24/25

Most Recent Stories

More News
GH Power, the Pioneering Clean Energy and Critical Materials Company, to Go Public through Business Combination with Matinas BioPharma

Following the transaction, the new public company will focus its efforts on the continued development and scale-up of GH Power’s technology platform, expanding project development activities in North...

MTNB : 0.2414 (-3.13%)
Matinas BioPharma Announces Strategic Business Combination with GH Power to Create Publicly Traded, Advanced Clean Energy and Green Hydrogen Company; Signs Definitive Agreement to Sell LNC Platform Technology and Lead Product Candidate MAT2203 to...

Will create publicly traded advanced clean energy company focused on modular carbon-free energy, green hydrogen, critical materials and industrial decarbonization  Business Combination expected to...

MTNB : 0.2414 (-3.13%)
Matinas BioPharma Receives Notice of Non-Compliance with NYSE American Continued Listing Standards and Acceptance of Plan to Regain Compliance

BEDMINSTER, N.J., June 26, 2026 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (the “Company”) (NYSE American: MTNB) announced today that on June 24, 2026, it received a notice (the “Notice”)...

MTNB : 0.2414 (-3.13%)
Matinas BioPharma Receives Notice of Non-Compliance with NYSE American Continued Listing Standards

BEDMINSTER, N.J., April 03, 2026 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (the “Company”) (NYSE American: MTNB) announced today that on April 2, 2026, it received a notice (the “Notice”)...

MTNB : 0.2414 (-3.13%)
Matinas BioPharma Appoints Seasoned Biotech Leaders to Board of Directors

GRCE : 2.33 (-0.85%)
ONVO : 2.04 (+1.49%)
MTNB : 0.2414 (-3.13%)
Matinas BioPharma Announces Agreement for the Acquisition of Preferred Stock and Appointment of Dr. Robin L. Smith to the Board of Directors

MTNB : 0.2414 (-3.13%)
Matinas BioPharma Appoints Evelyn D’An to Board of Directors as Audit Committee Chair

MTNB : 0.2414 (-3.13%)
Matinas BioPharma Receives NYSE Noncompliance Notice

MTNB : 0.2414 (-3.13%)
Matinas BioPharma Announces the Termination of MAT2203 Partnership Negotiations and Implements Immediate Workforce Reduction

MTNB : 0.2414 (-3.13%)
Matinas BioPharma Reports Second Quarter 2022 Financial Results and Highlights Recent Progress

75% of Patients Enrolled to Date in Cohort 4 of EnACT (MAT2203 in Cryptococcal Meningitis); Topline Data in Late Q3/Early Q4 2022 FDA Provides Flexibility...

MTNB : 0.2414 (-3.13%)

Business Summary

Matinas BioPharma is a clinical-stage biopharmaceutical company focused on enabling the delivery of life-changing medicines using its LNC platform technology. The Company's proprietary, disruptive technology utilizes lipid nano-crystals which can encapsulate small molecule drugs, oligonucleotides, vaccines,...

See More

Key Turning Points

3rd Resistance Point 0.2977
2nd Resistance Point 0.2823
1st Resistance Point 0.2619
Last Price 0.2414
1st Support Level 0.2261
2nd Support Level 0.2107
3rd Support Level 0.1903

See More

52-Week High 3.0900
Fibonacci 61.8% 1.9979
Fibonacci 50% 1.6606
Fibonacci 38.2% 1.3233
Last Price 0.2414
52-Week Low 0.2312

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.